Table 2.
Review of evidence of clozapine use in childhood psychosis.
| References | Drugs | Key findings | Remarks on side effects |
|---|---|---|---|
| Kumra et al. (33) | Haloperidol vs. clozapine | Clozapine outperforms haloperidol in terms of both positive and negative symptom control. | Sedation, drooling, and temporary neutropenia were the reported side effects. |
| Shaw et al. (34) | Olanzapine vs. clozapine | Clozapine showed superior response in mitigating negative symptoms, as measured by SANS score as compared to Olanzapine | Despite reports of increased heartrate and Blood Pressure and enuresis with clozapine, no children were removed from the trial. They found tachycardia in 70% of patients, but no change in blood pressure. |
| Sporn et al. (35) | NDMC, a clozapine metabolite, was favorably linked with clinical improvement when examined as an NDMC/clozapine ratio | Increased side effects in youngsters than adults, but they could not predict these events. | |
| Kumra et al. (36) | High dose olanzapine vs. clozapine | Among treatment-refractory patients, clozapine had a 66% response rate vs. 33% for olanzapine. | More advantage at a dose of 30 mg/day Olanzapine. |
| Kumra et al. (36) | Olanzapine to clozapine switchers | 70% of olanzapine-refractory individuals reacted to clozapine in an extended study. | Clozapine can cause a range of metabolic adverse effects. |